{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:03:29Z","timestamp":1783767809611,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases Intramural Research Program, National Institutes of Health","award":["NO1-AI-15444"],"award-info":[{"award-number":["NO1-AI-15444"]}]},{"DOI":"10.13039\/100008309","name":"Johns Hopkins Bloomberg School of Public Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008309","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013017","name":"Vanderbilt University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013017","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.vaccine.2013.07.064","type":"journal-article","created":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T21:15:19Z","timestamp":1376946919000},"page":"5772-5777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["The live attenuated chimeric vaccine rWN\/DEN4\u039430 is well-tolerated and immunogenic in healthy flavivirus-na\u00efve adult volunteers"],"prefix":"10.1016","volume":"31","author":[{"given":"Anna P.","family":"Durbin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangeci","family":"Kagucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Elwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberli","family":"Wanionek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Speicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Pletnev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.07.064_bib0005","series-title":"Fields Virology","first-page":"1192","article-title":"Flaviviruses","author":"Gubler","year":"2007"},{"key":"10.1016\/j.vaccine.2013.07.064_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.med.57.121304.131418","article-title":"West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States","volume":"57","author":"Hayes","year":"2006","journal-title":"Annu Rev Med"},{"issue":"July (4)","key":"10.1016\/j.vaccine.2013.07.064_bib0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jama.290.4.511","article-title":"Neurologic manifestations and outcome of West Nile virus infection","volume":"290","author":"Sejvar","year":"2003","journal-title":"JAMA"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2013.07.064_bib0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3201\/eid0907.030129","article-title":"Acute flaccid paralysis and West Nile virus infection","volume":"9","author":"Sejvar","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2013.07.064_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/vbz.2007.0137","article-title":"West Nile virus neuroinvasive disease incidence in the United States, 2002\u20132006","volume":"8","author":"Lindsey","year":"2008","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.vaccine.2013.07.064_bib0030","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268812001070","article-title":"Estimated cumulative incidence of West Nile virus infection in US adults, 1999\u20132010","volume":"141","author":"Petersen","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2013.07.064_bib0035","unstructured":"CDC. West Nile Virus (WNV) human infections reported to ArboNET, by State, United States, Available from: <http:\/\/www.cdc.gov\/ncidod\/dvbid\/westnile\/surv&controlCaseCount12_detailed.htm\/>; 2012 [cited 20.05.13]."},{"issue":"March (3)","key":"10.1016\/j.vaccine.2013.07.064_bib0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3201\/eid1603.090667","article-title":"Economic cost analysis of West Nile virus outbreak, Sacramento County, California, USA, 2005","volume":"16","author":"Barber","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2013.07.064_bib0045","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3201\/eid1010.030925","article-title":"West Nile virus economic impact, Louisiana, 2002","volume":"10","author":"Zohrabian","year":"2004","journal-title":"Emerging infectious diseases"},{"issue":"Spring (1)","key":"10.1016\/j.vaccine.2013.07.064_bib0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol"},{"issue":"February (6)","key":"10.1016\/j.vaccine.2013.07.064_bib0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.vaccine.2007.11.082","article-title":"Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3\u2019 untranslated region (3\u2019-UTR) or by exchange of the DENV-3 3\u2019-UTR with that of DENV-4","volume":"26","author":"Blaney","year":"2008","journal-title":"Vaccine"},{"issue":"August (33)","key":"10.1016\/j.vaccine.2013.07.064_bib0060","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1016\/j.vaccine.2008.05.075","article-title":"Evaluation of St. Louis encephalitis virus\/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys","volume":"26","author":"Blaney","year":"2008","journal-title":"Vaccine"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2013.07.064_bib0065","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/JVI.77.2.1653-1657.2003","article-title":"A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3\u2019 untranslated region is highly attenuated and immunogenic in monkeys","volume":"77","author":"Whitehead","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2013.07.064_bib0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0065-3527(03)61013-4","article-title":"Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis","volume":"61","author":"Lai","year":"2003","journal-title":"Adv Virus Res"},{"issue":"October (27\u201330)","key":"10.1016\/j.vaccine.2013.07.064_bib0075","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/S0264-410X(03)00488-2","article-title":"Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys","volume":"21","author":"Whitehead","year":"2003","journal-title":"Vaccine"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2013.07.064_bib0080","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/427780","article-title":"rDEN4 delta 30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers","volume":"191","author":"Durbin","year":"2005","journal-title":"J Infect Dis"},{"issue":"July\u2013August (4)","key":"10.1016\/j.vaccine.2013.07.064_bib0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4161\/hv.2.4.2944","article-title":"The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers","volume":"2","author":"Durbin","year":"2006","journal-title":"Hum Vaccin"},{"issue":"November (6)","key":"10.1016\/j.vaccine.2013.07.064_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/hv.2.6.3494","article-title":"rDEN2\/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults","volume":"2","author":"Durbin","year":"2006","journal-title":"Hum Vaccin"},{"issue":"February (7)","key":"10.1016\/j.vaccine.2013.07.064_bib0095","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.vaccine.2007.12.015","article-title":"Evaluation of the Langat\/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers","volume":"26","author":"Wright","year":"2008","journal-title":"Vaccine"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2013.07.064_bib0100","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A Single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2013.07.064_bib0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0042-6822(03)00450-1","article-title":"Molecularly engineered live-attenuated chimeric West Nile\/dengue virus vaccines protect rhesus monkeys from West Nile virus","volume":"314","author":"Pletnev","year":"2003","journal-title":"Virology"},{"issue":"September (40\u201341)","key":"10.1016\/j.vaccine.2013.07.064_bib0110","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.vaccine.2006.06.008","article-title":"Chimeric West Nile\/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity","volume":"24","author":"Pletnev","year":"2006","journal-title":"Vaccine"},{"issue":"Spring (1)","key":"10.1016\/j.vaccine.2013.07.064_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/vbz.2005.5.1","article-title":"Infectivity of West Nile\/dengue chimeric viruses for West Nile and dengue mosquito vectors","volume":"5","author":"Hanley","year":"2005","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2013.07.064_bib0120","doi-asserted-by":"crossref","first-page":"e1267","DOI":"10.1371\/journal.pntd.0001267","article-title":"A single dose of the DENV-1 candidate vaccine rDEN1\u039430 is strongly immunogenic and induces resistance to a second dose in a randomized trial","volume":"5","author":"Durbin","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2013.07.064_bib0125","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1073\/pnas.022652799","article-title":"From the cover: West Nile virus\/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy","volume":"99","author":"Pletnev","year":"2002","journal-title":"PNAS"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2013.07.064_bib0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3\u2019-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2013.07.064_bib0135","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/jmv.22033","article-title":"Microarray hybridization for assessment of the genetic stability of chimeric West Nile\/dengue 4 virus","volume":"83","author":"Laassri","year":"2011","journal-title":"J Med Virolo"},{"issue":"October (47)","key":"10.1016\/j.vaccine.2013.07.064_bib0140","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults \u226550 years of age","volume":"30","author":"Dayan","year":"2012","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2013.07.064_bib0145","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1128\/JVI.75.17.8259-8267.2001","article-title":"Tick-borne Langat\/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes","volume":"75","author":"Pletnev","year":"2001","journal-title":"J Virol"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2013.07.064_bib0150","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/viro.1999.9695","article-title":"Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis","volume":"257","author":"Guirakhoo","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2013.07.064_bib0155","series-title":"Vaccines","first-page":"959","article-title":"Yellow fever vaccine","author":"Monath","year":"2008"},{"key":"10.1016\/j.vaccine.2013.07.064_bib0160","first-page":"1","article-title":"Dengue viruses","volume":"16","author":"Schlesinger","year":"1977","journal-title":"Virol Monogr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13010505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13010505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:04:46Z","timestamp":1588968286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13010505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":32,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0264410X13010505"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The live attenuated chimeric vaccine rWN\/DEN4\u039430 is well-tolerated and immunogenic in healthy flavivirus-na\u00efve adult volunteers","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}